ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI's stock price shot up 8.8% on Monday . The stock traded as high as $1.88 and last traded at $1.86. 3,430,662 shares changed hands during mid-day trading, an increase of 870% from the average session volume of 353,838 shares. The stock had previously closed at $1.71.
ESSA Pharma Price Performance
The stock has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $1.69. The company has a market cap of $82.57 million, a price-to-earnings ratio of -2.95 and a beta of 1.56.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last issued its earnings results on Thursday, May 8th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. As a group, research analysts forecast that ESSA Pharma Inc. will post -0.42 EPS for the current year.
Hedge Funds Weigh In On ESSA Pharma
Several large investors have recently made changes to their positions in EPIX. DLD Asset Management LP purchased a new position in ESSA Pharma during the 1st quarter valued at about $290,000. Aldebaran Capital LLC lifted its position in shares of ESSA Pharma by 43.2% during the first quarter. Aldebaran Capital LLC now owns 569,294 shares of the company's stock worth $899,000 after purchasing an additional 171,771 shares in the last quarter. Deuterium Capital Management LLC purchased a new position in shares of ESSA Pharma in the first quarter valued at approximately $174,000. GTS Securities LLC purchased a new position in shares of ESSA Pharma in the fourth quarter valued at approximately $30,000. Finally, Squarepoint Ops LLC acquired a new position in shares of ESSA Pharma in the fourth quarter valued at approximately $26,000. 75.12% of the stock is currently owned by institutional investors and hedge funds.
About ESSA Pharma
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
